Examining Engagement Trends Among Participants in Hidradenitis Suppurativa Clinical Trials
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Hidradenitis Suppurativa
- Sponsor
- Power Life Sciences Inc.
- Enrollment
- 500
- Locations
- 1
- Primary Endpoint
- Number of hidradenitis suppurativa patients who decide to enroll in a clinical research
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
This study aims to uncover the factors driving patient decisions regarding enrollment, withdrawal, or re-engagement in hidradenitis suppurativa clinical trials. Understanding these factors will significantly improve the relevance and effectiveness of future research endeavors.
Ultimately, this trial endeavors to deepen our understanding of the factors impacting hidradenitis suppurativa clinical trial participation. Enhancing participation rates could accelerate the development of innovative treatments for this debilitating condition.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Aged ≥ 18 years old
- •Diagnosis of hidradenitis suppurativa
- •Able to comprehend the investigational nature of the protocol and provide informed consent
Exclusion Criteria
- •Female patients who are currently pregnant or nursing
- •Inability to perform regular electronic reporting
- •Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
Outcomes
Primary Outcomes
Number of hidradenitis suppurativa patients who decide to enroll in a clinical research
Time Frame: 3 months
Rate of hidradenitis suppurativa patients who remain in clinical trial to trial completion
Time Frame: 12 months